Last reviewed · How we verify
Imiquimod 5%: manufactured by Apotex
Imiquimod 5%: manufactured by Apotex is a TLR7 agonist Small molecule drug developed by Apotex Inc.. It is currently in Phase 3 development for Actinic keratosis, Basal cell carcinoma (superficial and nodular), Genital warts (external).
Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions and certain cancers.
Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions and certain cancers. Used for Actinic keratosis, Basal cell carcinoma (superficial and nodular), Genital warts (external).
At a glance
| Generic name | Imiquimod 5%: manufactured by Apotex |
|---|---|
| Sponsor | Apotex Inc. |
| Drug class | TLR7 agonist |
| Target | TLR7 (Toll-like receptor 7) |
| Modality | Small molecule |
| Therapeutic area | Dermatology, Oncology, Immunology |
| Phase | Phase 3 |
Mechanism of action
Imiquimod binds to TLR7 on immune cells, triggering the production of interferon-alpha and other cytokines that enhance local immune activation. This stimulates both innate and adaptive immune responses against abnormal cells or viral-infected cells in the skin. The resulting inflammation and immune cell infiltration lead to clearance of targeted lesions.
Approved indications
- Actinic keratosis
- Basal cell carcinoma (superficial and nodular)
- Genital warts (external)
- Cutaneous T-cell lymphoma (mycosis fungoides)
Common side effects
- Local skin irritation (erythema, erosion, excoriation)
- Pruritus
- Burning sensation
- Scabbing/crusting
- Systemic flu-like symptoms (fatigue, fever, myalgia)
- Lymphadenopathy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imiquimod 5%: manufactured by Apotex CI brief — competitive landscape report
- Imiquimod 5%: manufactured by Apotex updates RSS · CI watch RSS
- Apotex Inc. portfolio CI
Frequently asked questions about Imiquimod 5%: manufactured by Apotex
What is Imiquimod 5%: manufactured by Apotex?
How does Imiquimod 5%: manufactured by Apotex work?
What is Imiquimod 5%: manufactured by Apotex used for?
Who makes Imiquimod 5%: manufactured by Apotex?
What drug class is Imiquimod 5%: manufactured by Apotex in?
What development phase is Imiquimod 5%: manufactured by Apotex in?
What are the side effects of Imiquimod 5%: manufactured by Apotex?
What does Imiquimod 5%: manufactured by Apotex target?
Related
- Drug class: All TLR7 agonist drugs
- Target: All drugs targeting TLR7 (Toll-like receptor 7)
- Manufacturer: Apotex Inc. — full pipeline
- Therapeutic area: All drugs in Dermatology, Oncology, Immunology
- Indication: Drugs for Actinic keratosis
- Indication: Drugs for Basal cell carcinoma (superficial and nodular)
- Indication: Drugs for Genital warts (external)
- Compare: Imiquimod 5%: manufactured by Apotex vs similar drugs
- Pricing: Imiquimod 5%: manufactured by Apotex cost, discount & access